Better Therapeutics, Inc. (BTTX)

Market Cap	8.80M
Revenue (ttm)	n/a
Net Income (ttm)	-31.57M
Shares Out	47.40M
EPS (ttm)	-1.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,389,348
Open	0.180
Previous Close	0.196
Day's Range	0.172 - 0.199
52-Week Range	0.137 - 1.610
Beta	2.22
Analysts	Strong Buy
Price Target	6.00 (+3,131.02%)
Earnings Date	Nov 9, 2023

About BTTX

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, incl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 54
• Stock Exchange: NASDAQ
• Ticker Symbol: BTTX

Analyst Forecast

According to 2 analysts, the average rating for BTTX stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 3,131.02% from the latest price.

Price Target

$6.0

(3,131.02% upside)

Analyst Consensus: Strong Buy